Interestingly, Chiriaco et al. suggested the application of MET-CAR-T in gastric cancers not eligible for targeted therapy, due to a primary resistance, such as tumors with low MET amplification, or a secondary resistance, such as transformed cells developing activating mutations on downstream signal transducers under MET-TKI selective pressure [107]. This evidence concerns the gene MET and gastric cancer.